Skip to content
Review

The FSH reset hypothesis: optimizing spermatogenesis in azoospermia.

Jul 2026 · Current Opinion in Urology · 0 citations · 18 references
Medicine

TL;DR

The FSH reset hypothesis, in which a finite period of pituitary suppression reduces inefficient endogenous hormone and may allow receptor recovery before controlled recombinant FSH, is outlined and presented as a stepwise treatment algorithm for future investigation in selected men with spermatogenic failure.

Abstract

Purpose

OF REVIEW Elevated follicle-stimulating hormone (FSH) in primary hypogonadism is usually read as maximal but failing testicular stimulation, and affected men are often considered poor candidates for hormonal therapy. This is a hypothesis-generating narrative review rather than an evidence-based treatment recommendation. It re-examines that assumption and asks whether FSH bioactivity, rather than concentration alone, might shape the testicular response. RECENT

Findings

Circulating FSH is a mixture of glycosylation-dependent isoforms that differ in receptor-binding efficiency in experimental systems. Chronic gonadotropin excess can downregulate and desensitize the FSH receptor in animal and in vitro models. In principle, these mechanisms could combine to produce a state of functional FSH resistance, in which immunoreactive FSH is high while the effective signal in the testes is weaker. FSH suppression-associated rises in inhibin B, contemporary staged conditioning protocols, and stratification of hypergonadotropic men under the APHRODITE criteria are consistent with a strategy of temporary suppression before stimulation. SUMMARY We outline the FSH reset hypothesis, in which a finite period of pituitary suppression reduces inefficient endogenous hormone and may allow receptor recovery before controlled recombinant FSH. We then present a stepwise treatment algorithm as a model for future investigation in selected men with spermatogenic failure. The hypothesis is speculative and remains unproven in prospective trials.

View source

Similar papers

Review Open access Jul 2026

The extragonadal biology of gonadotropin hormones: should we rename these?

Current understanding of direct actions of FSH and LH on bone, adipose tissue, and brain and focus specifically on the detrimental health burden during and after the menopause: osteoporosis, obesity, and dementia are reviewed.

Se-Min Kim, Funda Korkmaz, Sorang Kang et al. · 0 citations
Review Open access Aug 2026

Re-assessment of the therapeutic LH window in normogonadotropic IVF patients

It is concluded that normogonadotropic IVF patients undergoing OS have a clearly defined therapeutic LH window below and above which clinical outcome is compromised.

Bernadette Mannaerts, Colin M. Howles, C. Y. Andersen · 0 citations
Review Open access Aug 2026

Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging

The traditional framework for FSH is presented alongside recent findings that warrant re-evaluation of its function as a hormone, particularly in women as a modifiable marker of endocrine aging.

D. Minich, Emily C. Hernandez, Caitlin Holmes et al. · 0 citations
Case report Open access Sep 2026

Gonadotropin-resistant ovary syndrome in a hypergonadotropic patient with FSHR/FSHB polymorphisms and abnormal karyotype

The combination of polymorphisms in the FSHR and FSHB genes and mosaicism for monosomy X and triple X supports an oocyte-related cause of infertility and suggests oocyte donation as the most effective treatment option for patients with a similar genetic profile.

Aleksandra Ivanoska Trajcevski, A. Juul, Lea Langhoff Thuesen · 0 citations
Review Open access Aug 2026

Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review

Current evidence suggests that peptide-based therapies may support endogenous hormonal signaling through targeted activation of the HPT axis, however, direct evidence demonstrating restoration of spermatogenesis or fertility following TRT-induced suppression remains limited, and important questions regarding long-term...

Ana-Maria Creţu, A. Kamar, A. Ciobîcă et al. · 0 citations
Review Open access Sep 2026

The Role of Clomiphene Citrate in Gonadotropin Stimulation Protocols in Poor Responders: A Mini-Review of Recent Clinical Evidence

Diminished ovarian reserve (DOR) and poor ovarian response (POR) remain among the most challenging conditions in assisted reproductive technology, and no optimal stimulation strategy has been established. Clomiphene citrate (CC), a selective estrogen receptor modulator that augments endogenous gonadotropin secretion an...

Maria T. Papadopoulou, Miltiadis Badagionis, Fotios Vlahos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.